Capital Increase Take-off for Natraceutical: Euro20 Million


Madrid - The Board of Spanish specialist for food, Natraceutical, approved in its April meeting the issue of 38,521,165 new shares, for a nominal amount of Euro3,852,116.5, allowing it to raise Euro20,031,005.80. The new shares will have the same rights as all bonds currently in circulation, taking effect from January 1, 2004, and with an issue price of Euro0.52.
Upon the approval of the prospectus by the Comisión Nacional de Mercado de Valores CNMV (National Stock Exchange Comission) , a 10-day period will be established to enable Natraceutical's shareholders to subscribe 5 new shares for every 19 old shares in their possession the day before this preferential subscription period commences and in which the rights, valued according to closing on April 22 at Euro0.075, will also be listed.
The Euro20 million , which Natraceutical will raise, will enable it to strengthen its resources and deal with projects which are included in the prospectus of its floating on the stock market, in addition to other product or business lines in which it's working.
Natraceutical currently markets 22 functional ingredients for the food industry. During 2003 and 2004 it has applied for five patents for functional ingredients and active principles, all derived from raw, natural materials, especially from the Mediterranean area. The company produces active compunds and biotechnological ingredients and develops functional foods as well. It also takes part in Biópolis, a biotechnological company directed at custom-made R&D activities for the food and pharmaceutical sectors, which was launched in April 2003 with the Consejo Superior de Investigaciones Científicas (Board of Scientific Research-CSIC), CAPSA and the Capital-Risk entity, TALDE. In 2003, Natraceutical achieved net profits of Euro2 million, thus multiplying six-fold its previous year's profits.
The world market for functional ingredients and nutraceuticals, whose main markets are the United States and Japan, rose to more than $34 billion in 2002, reflecting a growth of 9.2% compared with the previous year.



Madrid – Nowhere in the world, is the concentration of GM-sceptics higher than it is in Europe, but their reign is not supreme. On the south-western tip of the continent, Spain stands out for its “science-based agricultural...



Seville – Genetrix S.L. and the Botín Foundation will channel a 6m over the next three years into the new company Axontherapix SL. The public-private partnership will seek to develop an effective therapy for Parkinson’s Disease....



Pamplona – With a record-setting Biospain this year, the Spanish biotech industry has underpinned its role as a premier player in the sector in southern Europe. More than 1,400 business representatives flocked to Pamplona, where...



Bilbao – Spanish Progenika Biopharma S.A has gained the green light for sale of its LPLchip in Europe. The DNA chip, which has achieved the CE mark, detects approximately 120 mutations in the lipoprotein lipase (LPL) gene and...



Madrid – Responding to the current debate surrounding the reactome array investigation, Manuel Ferrer from the Institute of Catalysis and Petrochemistry in Madrid told EuroBiotechNews his team would “clarify all the scientific...



Madrid – When Chinese Premier Wen Jiabao met his Spanish colleague Jose Luis Rodriguez Zapatero on August 31st, he talked about the Mediterranean country’s role as an important economic partner for China, and said cooperation...



Madrid/Braunschweig - Spanish and German scientists who last year reported a groundbreaking technology that is able to identify the whole set of biochemical reactions in bacteria or cells, together with the enzymes involved, have...



Barcelona – While the cash-strapped Spanish government is being stripped of its AAA grade investment rating, one of the giants of the country’s life science industry is on a spending spree. Grifols, a producer of plasma protein...



Barcelona/Nantes – Biomarker-specialist TcLand Expression in Nantes has found an ally in the Vall d’Hebron University Hospital Research Institute (HVIR) in Barcelona. The French company and the Spanish clinic will work together...

Displaying results 21 to 30 out of 181

< Previous 21-30 Next >

© 2007-2015 BIOCOM


Product of the week



All Events

Stock list

All quotes


  • MEDIGENE (D)10.45 EUR7.51%
  • WILEX (D)3.65 EUR5.49%
  • SUMMIT (UK)4.03 GBP3.87%


  • 4SC (D)4.59 EUR-6.33%
  • BAVARIAN NORDIC (D)41.82 EUR-6.28%
  • BIOFRONTERA (D)2.06 EUR-5.50%


  • DBV Technologies (F)52.75 EUR16.9%
  • Allergy Therapeutics (UK)23.50 GBP15.3%


  • CHRONTECH PHARMA (S)0.01 SEK-50.0%
  • TRANSGENE (F)3.68 EUR-28.8%
  • NORDIC NANOVECTOR (N)25.20 NOK-26.5%


  • 4SC (D)4.59 EUR345.6%
  • ADOCIA (F)65.40 EUR336.0%
  • WILEX (D)3.65 EUR319.5%


  • CHRONTECH PHARMA (S)0.01 SEK-87.5%
  • ACTIVE BIOTECH (S)8.85 SEK-70.6%
  • NEOVACS (F)1.10 EUR-69.3%

No liability assumed, Date: 03.07.2015

Current issue

All issues